Benjamin F. Edwards & Company, Inc. Repligen Corp Transaction History
Benjamin F. Edwards & Company, Inc.
- $5.69 Billion
- Q2 2024
A detailed history of Benjamin F. Edwards & Company, Inc. transactions in Repligen Corp stock. As of the latest transaction made, Benjamin F. Edwards & Company, Inc. holds 101 shares of RGEN stock, worth $16,787. This represents 0.0% of its overall portfolio holdings.
Number of Shares
101
Previous 101
-0.0%
Holding current value
$16,787
Previous $19,000
31.58%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding RGEN
# of Institutions
479Shares Held
54.5MCall Options Held
341KPut Options Held
235K-
Black Rock Inc. New York, NY7.57MShares$1.26 Billion0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.39MShares$1.06 Billion0.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.04MShares$838 Million0.01% of portfolio
-
State Street Corp Boston, MA1.62MShares$270 Million0.01% of portfolio
-
Champlain Investment Partners, LLC Burlington, VT1.42MShares$236 Million1.34% of portfolio
About REPLIGEN CORP
- Ticker RGEN
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 55,491,200
- Market Cap $9.22B
- Description
- Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....